|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/15/18 Nymox Pharmaceutical Corp 6-K 3/31/18 36:1.2M Pubco Reporting … Inc/FA |
Document/Exhibit Description Pages Size
1: 6-K Report by a Foreign Issuer HTML 18K
2: EX-99.1 Quarterly Report for the Quarter Ended HTML 155K
3: EX-99.2 CEO Certification HTML 19K
4: EX-99.3 CFO Certification HTML 19K
11: R1 Document and Entity Information HTML 38K
12: R2 Consolidated Condensed Statements of Financial HTML 65K
Position
13: R3 Consolidated Condensed Statements of Financial HTML 15K
Position (Parenthetical)
14: R4 Consolidated Condensed Statements of Operations HTML 56K
(Unaudited)
15: R5 Consolidated Condensed Statement of Changes in HTML 35K
Equity (Unaudited)
16: R6 Consolidated Condensed Statements of Cash Flows HTML 54K
(Unaudited)
17: R7 Basis of preparation HTML 18K
18: R8 Liquidity, Going Concern and Managements Response HTML 16K
19: R9 Share capital HTML 49K
20: R10 Earnings per share HTML 22K
21: R11 Related Party Transactions HTML 25K
22: R12 Subsequent events HTML 19K
23: R13 Share capital (Tables) HTML 45K
24: R14 Earnings per share (Tables) HTML 21K
25: R15 Related Party Transactions (Tables) HTML 21K
26: R16 Share capital (Details) HTML 23K
27: R17 Share capital (Details 1) HTML 19K
28: R18 Share capital (Details 2) HTML 17K
29: R19 Share Capital (Details Narrative) HTML 22K
30: R20 Earnings per share (Details) HTML 20K
31: R21 Related Party Transactions (Details) HTML 22K
32: R22 Related Party Transactions (Details Narrative) HTML 19K
33: R23 Subsequent events (Details Narrative) HTML 41K
35: XML IDEA XML File -- Filing Summary XML 56K
34: EXCEL IDEA Workbook of Financial Reports XLSX 26K
5: EX-101.INS XBRL Instance -- nymx-20180331 XML 299K
7: EX-101.CAL XBRL Calculations -- nymx-20180331_cal XML 69K
8: EX-101.DEF XBRL Definitions -- nymx-20180331_def XML 103K
9: EX-101.LAB XBRL Labels -- nymx-20180331_lab XML 314K
10: EX-101.PRE XBRL Presentations -- nymx-20180331_pre XML 228K
6: EX-101.SCH XBRL Schema -- nymx-20180331 XSD 117K
36: ZIP XBRL Zipped Folder -- 0001640334-18-001003-xbrl Zip 37K
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the period ended March 31, 2018
Commission File Number: 001-12033
|
Nymox Pharmaceutical Corporation |
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(l): ¨
Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_____________
|
Exhibits |
|
|
| |
|
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
| ||
|
NYMOX PHARMACEUTICAL CORPORATION |
| ||
|
(Registrant) |
| ||
|
|
| ||
|
By: |
| ||
|
|
| ||
|
|
President and Chief Executive Officer |
| |
Date: May 15, 2018
|
3 |
| This ‘6-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/15/18 | None on these Dates | ||
| For Period end: | 3/31/18 | |||
| List all Filings | ||||